(Q43922318)

English

Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the grupo ginecologico Español para el tratamiento oncologico (GGETO)

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the grupo ginecologico Español para el tratamiento oncologico (GGETO) (English)

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

maternal health

0 references

1 reference

based on heuristic

inferred from title

endometrial adenocarcinoma

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

author name string

F. Calero

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

E. Asins-Codoñer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

J. Jimeno

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

F. Rodriguez Escudero

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

J. Mendaña

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

J. Iglesias

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

F. Matía

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

A. Armas

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

R. Díaz-Castellanos

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

J. Garzón

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1834118

5 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1834118

5 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:027753799190135Z?httpAccept=text/xml

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

https://api.elsevier.com/content/article/PII:027753799190135Z?httpAccept=text/plain

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

864-866

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Reporting results of cancer treatment

2

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

Experience with intermediate-dose (110-120 mg/m2) epirubicin

6

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

4-epidoxorubicin in recurrent cervical cancer

7

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer

10

1 reference

10.1016/0277-5379(91)90135-Z

https://api.crossref.org/works/10.1016/0277-5379(91)90135-Z

5 December 2022

Identifiers

10.1016/0277-5379(91)90135-Z

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43922318&oldid=1785142900"